Improving treatment strategies for different depressive disorders by discovery of novel drug target candidates and discriminatory diagnostic biomarkers.
Using molecular signaling profile in white blood cells measured by highly-sensitive mass spectrometry (MS)-based proteomics in the differential diagnosis between major depressive disorder and bipolar disorder.
Inflammation-based stratification for immune-targeted Augmentation in major depressive disorder (INSTA-MD).
Burnout and depressive disorder with atypical features: Are they both mood disorders or not? | Burn-out en depressie met atypische kenmerken: Zijn het beide stemmingsstoornissen of niet?
Previous disorders and depression outcomes in individuals with 12-month major depressive disorder in the World Mental Health surveys
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder
Screening for depressive and anxiety disorders among adolescents in Indonesia : formal validation of the centre for epidemiologic studies depression scale : revised and the Kessler psychological distress scale
USE OF COMPOUNDS THAT MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
Use of compounds that selectively modulate astrocytic release of substances through hemichannels of connexins and pannexins, without influencing gap junctions, for the treatment of psychiatric disorders
COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS